CIBC Asset Management
SYRS

CIBC Asset Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

CIBC Asset Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,398
Closed -$82.4K – 1219
2024
Q1 		$82.4K Hold
15,398
– – ﹤0.01% 1095
2023
Q4 		$120K Hold
15,398
– – ﹤0.01% 1046
2023
Q3 		$60.8K Hold
15,398
– – ﹤0.01% 1019
2023
Q2 		$48.5K Hold
15,398
– – ﹤0.01% 1067
2023
Q1 		$41.1K Buy
+15,398
New +$59.7K ﹤0.01% 1041

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CIBC Asset Management's SYRS Position: Q2 2024 in Review

CIBC Asset Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 15,398 shares — an estimated $82.4K sold.

CIBC Asset Management first reported a position in SYRS in Q1 2023 and held it in 5 quarters. The position peaked at $120K in Q4 2023. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

  • CIBC Asset Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • CIBC Asset Management sold 15,398 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $82.4K.
  • CIBC Asset Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 5 quarters.
  • CIBC Asset Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $120K in Q4 2023.
  • 70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on CIBC Asset Management's 13F filing for Q2 2024, filed 1 Aug 2024.